



**NUCALA® (MEPOLIZUMAB) ORDER FORM**

(\* - Required Fields)

<input type="checkbox"/> <b>New Referral</b>	<input type="checkbox"/> <b>Order Renewal</b>	<input type="checkbox"/> <b>Medication/Order Change</b>
<input type="checkbox"/> <b>Benefits Verification Only</b>	<input type="checkbox"/> <b>Discontinuation Order</b>	

**PATIENT INFORMATION**

NAME*:		DOB*:	SEX:    M    F	
ADDRESS:			PHONE:	
WEIGHT:	LBS	KG	HEIGHT:	EMAIL:
ALLERGIES:				

**PHYSICIAN INFORMATION**

PHYSICIAN NAME*:			PRACTICE NAME:		
ADDRESS:			OFFICE CONTACT*:		
PHONE:	FAX:	EMAIL (FOR UPDATES):			

**NUCALA ORDER\***

(SELECT ONE OF THE FOLLOWING)

ICD-10\*: \_\_\_\_\_

Dosing: 100 mg administered subcutaneously once every 4 weeks

**OR**

Dosing: 300 mg as 3 separate 100-mg injections administered subcutaneously once every 4 weeks

Physician Signature\* \_\_\_\_\_ Date\*(Order is Valid for One Year) \_\_\_\_\_  
*Infusion will be administered per MPP policy and protocols*

**REQUIRED DIAGNOSIS:**

Severe Asthma  
 Eosinophilic Asthma  
 Eosinophilic Granulomatosis with Polyangiitis  
 Other \_\_\_\_\_

**REQUIRED DOCUMENTATION CHECKLIST:**

Patient Demographics  
 Insurance Card/Information  
 Clinical/Progress Notes supporting DX  
 Current Medication List and H&P  
 Absolute Eosinophil Count (> 300 in prior 12mos or > 150 in prior 6 weeks)  
 Anti-neutrophil cytoplasmic antibody (ANCA) positive within 6 months  
*(Required for Eosinophilic Granulomatosis with Polyangiitis)*

Last Infusion/Injection Date: \_\_\_\_\_

**STANDING LAB ORDERS:**     CMP     CBC     CRP     ESRP     HFR     UA

Labs to be drawn by Infusion Center    Frequency \_\_\_\_\_

**NOTES/ADDITIONAL COMMENTS:**

**Locations:**

-----Colorado-----

Lakewood

-----Florida-----

Fort Myers<sup>Coming Soon</sup>  
 Jacksonville  
 Kissimmee<sup>Coming Soon</sup>  
 Port St. Lucie  
 Winter Park

-----Texas-----

Arlington  
 Cedar Hill  
 Dallas  
 Denton  
 Ft. Worth<sup>Coming Soon</sup>  
 Irving  
 Rockwall  
 Southlake  
 Lewisville  
 Plano  
 Tyler